anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
NEW MATERIAL:The compound of formula I [R is H or lower alkyl; A is group of formula II (R&lt;1&gt; is H or lower alkyl) or -CO-]. EXAMPLE:2-Amino-7-( 1-hydroxy-1-methyl )-ethyl-5-oxo-5H-[ 1 ]benzopyrano[ 2,3-b]pyridine-3-carboxylic acid. USE:Anti-allergic agent. Useful as a preventive and remedy for allergic diseases such as allergic asthma, allergic dermatitis, hay fever, etc. PREPARATION:The compound of formula I can be prepared by hydrolyzing the compound of formula II (R&lt;2&gt; is lower alkyl). The alkali metal salt and organic amine salt of the compound of formula I have high solubility in water, and the solution has high stability. Accordingly the compound is convenient to be prepared in the form of drug such as injection, solution, etc.
Pyrrolobenzimidazoles of the formula:   &lt;IMAGE&gt;   are useful for treatment of heart and circulatory diseases. R1 is substituted phenyl; or optionally substituted naphthyl or a five- or six-membered heterocyclic group which can be condensed with a phenyl ring to form a bicyclic radical. R2 is hydrogen, alkyl, alkenyl or cycloalkenyl; R3 is alkyl, alkenyl or hydroxyalkyl or with R2 together forms cycloakylene; or R2 and R3 together form alkylidene or cycloalkylidene. R4 is hydrogen or lower alkanoyl. X is a valency bond, alkylene, vinylene, imino or carbonylamino. T stands for two hydrogen atoms. When X is a valency bond, R1 can also be hydrogen, hydrocarbyl which may also contain oxygen, amino, sulfur, carbonyl and sulfonyl groups. When X is imino or carbonylamino or when R1 is a bicyclic radical, T can also be oxygen. The compounds also include the tautomers and physiologically acceptable salts with inorganic and organic acids.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for inactivating viruses in a virus-containing blood product.  &lt;P&gt;SOLUTION: A solvent/cleanser treatment has been adopted to inactivate enveloped viruses in a blood product. It has been considered that the concentrations of 1.0 % of a solvent and 0.3 % of tri-n-butyl phosphate are necessary for firmly removing the activity of the viruses, but the inventor of the present invention has show the effect of fractionation and nanofiltration on the preparation of immune gamma globulin. Such treatment needs the remarkably reduced concentrations of the solvent and the cleanser. Such the reduced amounts of the solvent and the cleanser are connected to possibility to a relatively high yield and a reduced treatment cost, and to a relatively high efficiency in their removal after the inactivation.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject extract not having a problem on color, smell and safety, giving effects for improving skin roughness, improving keratin, beautifying skins, restroring hair, etc., and useful as a medicine for treating heart diseases, reciprocatory organ diseases, central nervous system diseases, etc., by subjecting the body of a labiate: Coleus forskolhii Brig., to a supercritical extraction method. SOLUTION: This forskolin-containing extract is obtained by subjecting the whole body or root portions of a labiate: Coleus forskolhii Brig., to a supercritical extraction method using a supercritical fluid. The extract is preferably obtained by subjecting the labiate: Coleus forskolhii Brig. to a supercritical extraction method using carbon dioxide as a supercritical fluid at a pressure of 73-200 kg/cm&lt;2&gt; , removing the first extract and again subjecting the residue to the supercritical extraction method using carbon dioxide at a pressure 200-500 kg/cm&lt;2&gt; . A solvent for assisting the extraction is an organic solvent (preferably ethanol). In the supercritical extraction method, the plant is heated at the critical temperature of the supercritical fluid or higher, preferably at 40-100 deg.C. The extract is administered at a daily dose of 0.1-10 mg (as forskolin) per adult.
1,161,333. Hog cholera vaccine. CHAS. PFIZER &amp; CO. Inc. 31 Oct., 1966 [6 May, 1966], No. 48762/66. Heading A5B. Inactivated hog cholera vaccine is prepared by growing a vaccine virus &#39;by infecting a swine tissue culture monolayer e.g. swine testicle tissue with virulent hog cholera virus at a pH of 7.2 to 7.6 until substantial virus replication has occurred, freezing said resulting vaccine virus followed by thawing said vaccine virus and recovering the virulent virus, inactivating said virulent virus by (i) combining said virulent virus with aqueous toluidine blue said toluidine being blue added in an amount to provide a final concentration of 2 mcgs. of toluidine blue per ml. of vinus, and irradiating the resulting mixture with light or by (ii) use of hydroxylamine or ethylene oxide, and harvesting the inactivated vaccine (product. The harvesting of the inactivated product Imay be performed by absorbing the virus on hydrated aluminium oxide to precipitate a mixture comprising inactivated virus and hydrated aluminium oxide and subsequently reconstituting the precipitate in phosphate buffered saline.
PURPOSE: To obtain a cosmetic, having high humectant effects with persistence and effective in caring for the skin or hair. CONSTITUTION: This cosmetic contains 1-50wt.% phosphoric triester of the formula (R&lt;1&gt; is a 12-24C alkyl or alkenyl; R&lt;2&gt; is a 6-24C alkyl, alkenyl or aryl; R&lt;3&gt; is a 1-6C alkyl, alkenyl or aryl) and 2-90wt.% polyol-based humectant (e.g. dipropylene glycol). The mixing ratio of the compound of the formula to the polyol-based humectant is preferably about 1/2. Furthermore, both the ingredients are blended with a hydrophilic humectant ingredient having &gt;=10wt.% solubility in the polyol-based humectant at 20 deg.C (e.g. dipropylene glycol) and an optional ingredient such as an oil, a surfactant, an ultraviolet light absorber, a humectant or a chelating agent and prepared into an oily, an emulsified or a water-based cosmetic. The cosmetic is especially suitable as a skin or a hair cosmetic requiring humectant effects such as caring for rough skin, hair, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a well-granulative granulated product containing a dried product of plant extract such as crude drug extract powder or Chinese herbal medicine extract powder, and to provide well-disintegrable tablets using the above granulated product(granules).  &lt;P&gt;SOLUTION: The method for producing the plant extract-containing granulated product(granules) comprises admixing/dispersing precipitated silica in water followed by addition of plant extract dried particles and making an agitation and granulation and then drying. By this method, the objective granulated product(granules) containing a dried product of plant extract such as crude drug extract powder or Chinese herbal medicine extract powder can be practically produced. The tablets made using the above granulated product(granules) are good in disintegrability. This method is particularly useful when tablets rich in such a dried product of plant extract are to be produced.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe hairdye capable of dyeing the hair without adsorption of a coloring matter (an acid dye) on the skin (e.g. scalp), hardly causing discoloration of the coloring matter, and free from bad effects such as the damage of the hair, and further to provide a method for dyeing the hair by using the hairdye.  &lt;P&gt;SOLUTION: The hair is dyed by using (A) an acid dye having ≤1,000 molecular weight, and (B) a water-soluble polymer, especially a nonionic water-soluble polymer (e.g. a hydroxyethylcellulose) as a thickener present in (C) water and/or a water-soluble organic solvent within a neutral pH region of 6.5-7.5 without formulating an acid such as citric acid, or within an alkaline pH region of 7.0-11.0 regulated by formulating (D) a proper pH regulator when dyeing the hair by the hairdye. As a result, the dye penetrates into the inside of the hair and the inside of the hair fiber is dyed without causing adsorption of the coloring matter on the surface of the hair and the skin. The objective hairdye is provided by using the phenomena. The method for dyeing the hair by using the hairdye is also provided.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Patients with chronic renal failure who are being treated with hemodialysis experience pain during invasive intervention with arteriovenous fistula. This condition negatively affects hemodialysis patients and leads to a decrease in their quality of life. In order to reduce the pain and fear experienced during arteriovenous fistula intervention, it is recommended to use pharmacological methods as well as nonpharmacological methods. Antistress ball, which is one of the nonpharmacological methods, reduces pain during arteriovenous fistula intervention by causing distraction in hemodialysis patients, but its effect on fear of pain is not yet known. Of the other nonpharmacological methods, the valsalva maneuver reduces pain during vascular intervention, but the pain and fear of pain during arteriovenous fistula intervention have not yet been investigated. In the same way, the effects of skin cooling device on pain and fear of pain during arteriovenous fistula intervention are unknown. The aim of this randomized controlled trial is to; to determine the effect of the antistress ball, valsalva maneuver and skin cooling device, which are one of the nonpharmacological methods applied to hemodialysis patients, on the level of pain and fear of pain due to arteriovenous fistula cannulation. This study will be conducted in an experimental type and 60 patients receiving hemodialysis treatment at X State Hospital hemodialysis unit will form the sample of the study. All patients in the experimental group will be given nonpharmacological applications (antistress ball, valsalva maneuver and skin cooling application) for 8 weeks, three times a week. The control group will not be given any intervention and will receive routine treatment. The 'Pain Catastrophization Scale' will be applied to the experimental and control groups before, in the middle and after the research. The 'Visual Analog Pain Scale\&amp;#34; will be used to determine the pain severity of hemodialysis patients before and after arteriovenous fistula intervention.
PROBLEM TO BE SOLVED: To simply and objectively examine a part where a drug acts or a part influenced by a stress, by taking out a digestive canal of a experiment animal, to which the drug is administered or the stress is loaded and, measuring automatic motion of the organ. SOLUTION: A drug to be tested is administered to an animal once or continuously, and several parts of digestive organs are taken out, e.g. 30 minutes to three hours later. A cut piece of the extracted digestive canal is suspended in a nutrition solution such as Tyrode&#39;s solution or the liken in a Magnus tube. An automatic motion of the digestive canal is measured and analyzed while a mixed gas (approximately 95% of oxygen and approximately 5% of carbon dioxide) is supplied at about 35 deg.C of water temperature. Although the automatic motion of the digestive canal continues for about 7-8 hours after the extraction, the motion is stable about 1-3 hours later after the extraction, and therefore, should be measured during this time.  When a stress is loaded to the animal, for example, by soaking and confining the animal in water, the automatic motion can be evaluated in the same manner. Moreover, a contraction waveform of the automatic motion is divided, expressed numerically and analyzed statistically in terms of a contraction height, a contraction force, a contraction area, a contraction frequency, etc., thereby, a more objective evaluation is achieved.
The invention discloses a traditional Chinese medicine formula for treating pneumonia of goat. The traditional Chinese medicine formula is composed of the following components by weight: 25 to 40 grams of mulberry leaf, 25 to 40 grams of bitter apricot kernel, 20 to 30 grams of adenophora stricta, and 15 to 25 grams of fritillaria cirrhosa. The preparation method comprises the following steps: putting the components mentioned above into a pot, adding 500 to 800 mL of drinking water, decocting the raw materials for 15 to 20 minutes, cooling, and removing dregs. The traditional Chinese medicine formula has the functions of clearing heat, removing toxin, clearing the lung heat, moistening dryness, dispelling wind-heat, killing bacteria, and eliminating inflammation, and can effectively treat goat&#39;s pneumonia caused by wind cold. The pneumonia of goat can be cured after 5 to 7 doses. The effective rate is 92 to 95%.
PURPOSE:To obtain an additive useful in a desired state such as gel-like or powdery state and especially useful as a thickening agent for coating by treating a clay mineral with a specific cationic surfactant to make interior of layer lipophilic and then adding a lipophilic substance thereto. CONSTITUTION:A 10-200 milliequivalent cationic surfactant being a primary, secondary or tertiary amine salt or a quaternary ammonium salt, having two or more &gt;=10C alkyl groups and containing at least one or more kinds of ester bond, ether bond and amine bond [e.g. N-(3-alkoxy-2-hydroxypropyl) trialkylammonium halide] is added to 100g clay mineral (e.g. montmorillonite) and water is further added thereto, and the mixture is sufficiently stirred or kneaded. The blend is washed with water, dehydrated and then washed with a mixed liquid of water and a hydrophilic organic solvent (e.g. methanol) and powdered by vacuum drying, etc. A liquid lipophilic substance (e.g. liquid paraffin) is added thereto and mixed with the powder to provide the objective composition.
502,410. Cosmetics. DEHN, F. B. (Factor &amp; Co., M.) Sept. 11, 1937, No. 24820. Drawings to Specification. [Class 81 (i)] A cosmetic preparation, such as a powder or foundation cream, adapted for use on individuals to be photographed or panchromatic type emulsions comprises white and coloured pigments so blended that the preparation has a high reflection coefficient to light of wavelengths of about 6200 to 6500 A and lower reflection coefficients to light of shorter wavelengths, the reflection coefficient to light within the range 4000 to 4500 A being 45 per cent to 75 per cent of the reflection coefficient to light within the range 6200 to 6500 A. The reflection coefficients of the preparations are ascertained by spectrographio methods. The pigments employed should consist to the extent of 50 per cent or over, of white pigments such as titanium and zinc oxides. The coloured pigments comprise materials such as ivoryblack, blue and red lakes, ochre, and substances used in the art as sienna and umber substitutes. Mineral oils, vegetable oils, and mixtures thereof with or without alcohols, wetting-agents, &amp;c. are used as vehicles.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a bathing agent which can give an expectation to a user, especially a bathing pleasure to an infant, because a toy can immediately visually not be checked, even when a toy-sealed member is dissolved to expose the toy.  &lt;P&gt;SOLUTION: This bathing agent is characterized by providing the following requirements. (1) The bathing agent comprises a bathing agent-sealed member 2 in which the bathing agent is sealed, and a toy-sealed member 4 in which the toy 3 is sealed. (2) The bathing agent has a foaming property, and covers the surface of bath water, when foamed. (3) The toy-sealed member is soluble in water.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The present invention relates generally to the concrol of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nuc&#39;cotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate In the control of mammalian body weight. The nucleotidc sequences in object represent the genes corresponding to the murinc and human OB gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypcptidc product of [he gene in question functions as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polyrncrasc chain reaction (PCR1 amplification, i.e., synthetic or natural oligonuclcotidcs. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, opcrativcly associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfectcd or transformed with an appropriate expression vector, and correspondingly, to the use of die abovc-mcmioncd constructs in the preparation of the modulators of the invention. Also provided arc antibodies lo the OB polypcptidc. Moreover, a mc:hod for modulating body weight of a mammal is provided, [n specific examples, genes encoding two isoforrns of both the murinc and human OB polypcptidcs arc provided.
The present invention relates to a novel Bacillus subtilis strain that exhibits insecticidal, antifungal and antibacterial activity. The supernatant of the strain contain effective insecticidal, antifungal and antibacterial agents. Also included in the invention is a solvent extractable, small molecular weight (&lt; 10,000 Dalton) corn rootworm-active metabolite produced in the supernatant. Also included in the invention are methods of protecting or treating plants from fungal and bacterial infections and corn rootworm infestations using whole broth culture or supernatant obtained from the novel Bacillus subtilis strain. The invention also includes novel antifungal and antibacterial compounds designated agrastatins and a novel combination comprising an A-type iturin, a plipastatin, a surfactin and an agrastatin. Methods of treating or protecting plants from fungal and bacterial infections and corn rootworm infestations comprising administering the novel agrastatins and the novel combination are also provided.
The present disclosure relates to devices and processes for monitoring attributes of a user&#39;s physical activity (e.g., workout) or inactivity, and to user interfaces (e.g., an activity indicator) for displaying the same. In some examples, a device determines whether physical activity corresponds to a first type based on a first set of criteria, and whether physical activity corresponds to a second type based on a second set of criteria. In some examples, the device controls an inactivity timer that measures user´s inactivity. In some examples, the device displays a first visual representation of an attribute or amount of a first type of physical activity, and a second visual representation of an attribute or amount of a second type. In some examples, the device displays a third visual representation of an attribute or amount of a third type of activity. In some examples, the third visual representation corresponds to user&#39;s inactivity.
The present invention provides a novel compound having a superior Na&lt;+&gt; channel inhibitory activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them.In the formula, the ring A represents a ring represented by the formula:(wherein R&lt;1 &gt;represents a hydrogen atom etc.; and R&lt;2 &gt;represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C1-6 alkylene group etc.; Z represents an optionally substituted C6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.
The compounds of formula I are obtained by reacting 3-nitro-4-halogeno-benzoic acid derivatives of formula II with compounds of formula III and subsequent reduction of the nitro group. The reaction is carried out in the presence of copper powder. The substituents in formulae I, II and III have the meanings given in Claim 1. The radicals B and R&lt;1&gt; can be cleaved by acid or alkaline hydrolysis before or after the reduction of the nitro group. The compounds obtained can be used as intermediates for the preparation of diuretics and saluretics. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for inhibiting a plasminogen activator inhibitor(PAI) by a plant ingredient that can be taken in as a food.  &lt;P&gt;SOLUTION: The technique comprises using an extract from a plant belonging to Zingiberaceae family such as Curcuma zedoaria ROSC., Crucuma longa L. or Zingiber officinale ROSC. as a PAI-1 inhibitor. In this technique, the plant extract is obtained preferably by removing a polar portions from the hydrous ethanol extract, and among the steps 1 to 3 described below, is obtained preferably by the step 2 or 3: (step 1) The plant body of the above plant is subjected to extraction with a 50-80% ethanol aqueous solution followed by concentration. (step 2) The product obtained by the step 1 is subjected to liquid-liquid extraction with n-hexane and water to obtain a n-hexane phase. (step 3) Ethyl acetate is added to the aqueous phase obtained by the step 2 followed by adding water as desired and then conducting a liquid-liquid extraction to obtain an ethyl acetate phase.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention comprises compounds of the general formula: &lt;FORM:0863552/IV (b)/1&gt; and their acid addition salts, wherein R1 is a methyl group, R2 is a hydrogen atom or an alkyl group (C1-4) and R3 + R4 is a trimethylene or tetramethylene group, thus forming a 5 or 6 membered ring with the carbon and the nitrogen atoms adjacent R4 and R3 respectively, and the preparation thereof by condensing a phenthiazine of the general formula:  &lt;FORM:0863552/IV (b)/2&gt; with a haloalkyl amine of the general formula:  &lt;FORM:0863552/IV (b)/3&gt; wherein X is a chlorine or bromine atom, if desired in the presence of an alkaline condensation agent and a solvent, and further if desired converting the base into an acid addition salt. 2-(N-Methyl-pyrrodidyl-21)-1- chlorolthaneis prepared from the corresponding ethanol by reaction with thionyl chloride. Specifications 802,726 and 863,547 also are referred to.ALSO:Pharmaceutical compositions comprise an inert diluent and compounds of the general formula &lt;FORM:0863552/VI/1&gt; or an acid addition salt thereof, wherein R1 is a methyl group, R2 is a hydrogen atom or a C1-4 alkyl group and R3 and R4 is a tri- or a tetramethylene group, thus forming a 5- or 6-membered ring with the carbon and the nitrogen atoms adjacent to R4 and R3, respectively. Compositions include tablets and solutions for both parenteral and local use.  Acid addition salts include the hydrochlorides, hydrobromides, sulphates, citrates, tartrates, succinates, maleates, acetates, benzoates and hexahydrobenzoates. Specifications 802,726 and 863,547 also are referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a stable transparent multi-component composition useful for the delivery of water soluble active agents to animals.  &lt;P&gt;SOLUTION: The compositions are formulated with a mixture of an oil phase, an aqueous phase and a surfactant system, along with the active agent to be delivered to the animal. The compositions are especially formulated to be incompatible with capsules such as gelatin and starch capsules. The aqueous phase of the compositions contains a substantial amount of polyethylene glycol and can optionally also contain a plasticizer. Preferable active agents are protainaceous materials.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT